Update on ASCVD Risk Assessment and Management

Join our virtual grand rounds to hear about recent major developments in lipid management to prevent atherosclerotic cardiovascular disease events.

Live Broadcast
1.00 available credits
Information
October 13, 2020
12:00 PM - 01:00 PM EDT
Online
Update on ASCVD Risk Assessment and Management
Choose a format
Details
Presenters
Comments
  • Overview

    This grand rounds activity features a leading expert in lipidology who will address the management of atherosclerotic cardiovascular disease (ASCVD) event risk with adjunctive therapies to statin use. Dr. James Underberg (NYU Langone) provides succinct information and practical clinical advice on 5 key areas of lipid management to prevent ASCVD events: 1) key concepts of the 2018 Multisociety Blood Cholesterol Guidelines; 2) triglycerides, their remnants, and their relationship to ASCVD; 3) the latest large-scale clinical trials on lipid-lowering therapies; 4) omega-3 fatty acids as statin adjuncts in ASCVD event reduction; and 5) practical considerations on the use of statins and statin adjuncts.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host: 

    James A. Underberg, MD, MS, FACP, FNLA
    Clinical Lipidology
    Clinical Assistant Professor of Medicine
    NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
    Director, Bellevue Hospital Lipid Clinic
    Past-President National Lipid Association 
    President American Board of Clinical Lipidology 
    New York, NY

    Consulting Fees: Ambry, Amgen
    Speakers Bureau: Alexion, Amarin, Amgen, Sanofi
    Contracted Research: Aegerion, Pfizer
    Advisory Board: Alexion, Amarin, Ambry, Amgen, Esperion, Medicines Company, Regeneron, Sanofi

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD has nothing to disclose.
    • Jill Freeman has nothing to disclose.
    • Kathleen Wickman has nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients who are at risk for a major cardiovascular event.  After participating in this educational activity, participants should be better able to:

    • Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
    • Appreciate the difference between omega-3 fatty acids and their formulations and how they to impact ASCVD events, including the negative role of dietary supplements
    • Use information on the clinical utility of adjuncts to statin therapy to improve the management of patients with or at high risk of ASCVD events
  • Target Audience

    This activity is designed to meet the educational needs of family practitioners, internists, cardiologists, endocrinologists, lipidologists, diabetologists, women’s healthcare providers, and allied health professionals. 

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Details
Presenters
Comments
  • Overview

    This grand rounds activity features a leading expert in lipidology who will address the management of atherosclerotic cardiovascular disease (ASCVD) event risk with adjunctive therapies to statin use. Dr. James Underberg (NYU Langone) provides succinct information and practical clinical advice on 5 key areas of lipid management to prevent ASCVD events: 1) key concepts of the 2018 Multisociety Blood Cholesterol Guidelines; 2) triglycerides, their remnants, and their relationship to ASCVD; 3) the latest large-scale clinical trials on lipid-lowering therapies; 4) omega-3 fatty acids as statin adjuncts in ASCVD event reduction; and 5) practical considerations on the use of statins and statin adjuncts.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host: 

    James A. Underberg, MD, MS, FACP, FNLA
    Clinical Lipidology
    Clinical Assistant Professor of Medicine
    NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease
    Director, Bellevue Hospital Lipid Clinic
    Past-President National Lipid Association 
    President American Board of Clinical Lipidology 
    New York, NY

    Consulting Fees: Ambry, Amgen
    Speakers Bureau: Alexion, Amarin, Amgen, Sanofi
    Contracted Research: Aegerion, Pfizer
    Advisory Board: Alexion, Amarin, Ambry, Amgen, Esperion, Medicines Company, Regeneron, Sanofi

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD has nothing to disclose.
    • Jill Freeman has nothing to disclose.
    • Kathleen Wickman has nothing to disclose.
  • Learning Objectives

    The goal of this activity is to enable effective collaboration and communication between the members of the professional teams who care for patients who are at risk for a major cardiovascular event.  After participating in this educational activity, participants should be better able to:

    • Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
    • Appreciate the difference between omega-3 fatty acids and their formulations and how they to impact ASCVD events, including the negative role of dietary supplements
    • Use information on the clinical utility of adjuncts to statin therapy to improve the management of patients with or at high risk of ASCVD events
  • Target Audience

    This activity is designed to meet the educational needs of family practitioners, internists, cardiologists, endocrinologists, lipidologists, diabetologists, women’s healthcare providers, and allied health professionals. 

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free